Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Two RNAi-Related Patent Applications: Feb 14, 2008

Premium
Title: RNA Interference-Mediated Treatment of Alzheimer’s Disease Using Short Interfering Nucleic Acid
 
Number: 20080032942
 
Filed: June 27, 2003
 
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
 
The invention, the patent application’s abstract states, “concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic-discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid … capable of mediating RNA interference against beta-secretase, amyloid precurson protein, pin-1, presenillin 1, and/or presenillin 2 gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1, and/or PS-2 expression or activity.”
 

 
Title: Polycationic Compositions for Cellular Delivery of Polynucleotides
 
Number: 20080033156
 
Filed: July 17, 2007
 
Lead Inventor: Chandra Vargeese, Sirna Therapeutics (Merck)
 
According to the patent application’s abstract, the invention “relates to delivery of biologically active molecules to cells. Specifically, the invention relates to polycationic compositions, polymers, and methods for delivering nucleic acids, polynucleotides, and oligonucleotides … including short interfering RNA, ribozymes, and antisense, or peptides, polypeptides, proteins, antibodies, hormones, and small molecules, to cells by facilitating transport across cellular membranes epithelial tissues and endothelial tissues. The compositions and methods of the invention are useful in therapeutic, research, and diagnostic applications that rely upon the efficient transfer of biologically active molecules into cells, tissues, and organs.”

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.